PHWM
ABBV icon

Palatine Hill Wealth Management’s AbbVie ABBV Stock Holding History

Palatine Hill Wealth Management’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$304K Buy
1,207
+158
+15% +$34K 0.24% 43
2026
Q1 		$228K Hold
1,049
– – 0.2% 46
2025
Q4 		$240K Buy
+1,049
New +$239K 0.19% 46

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Palatine Hill Wealth Management's ABBV Position: Q2 2026 in Review

Palatine Hill Wealth Management increased its AbbVie (ABBV) stake by 15% in Q2 2026, buying an estimated $34K and bringing the position to 1,207 shares worth $304K. The position accounts for 0.24% of the portfolio, ranked #43.

Palatine Hill Wealth Management first reported a position in ABBV in Q4 2025 and has held it in 3 quarters since. 4,234 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Palatine Hill Wealth Management held 1,207 shares of AbbVie worth $304K as of Q2 2026.
  • Palatine Hill Wealth Management bought 158 AbbVie shares in Q2 2026, an estimated $34K.
  • AbbVie made up 0.24% of Palatine Hill Wealth Management's portfolio in Q2 2026, its #43 holding.
  • Palatine Hill Wealth Management first reported a position in AbbVie in Q4 2025 and has held it in 3 quarters since.
  • 4,234 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Palatine Hill Wealth Management's 13F filing for Q2 2026, filed 7 Aug 2026.